Liberty Mutual Group Asset Management Inc. decreased its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 23.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,824 shares of the medical instruments supplier’s stock after selling 1,184 shares during the period. Liberty Mutual Group Asset Management Inc.’s holdings in C.R. Bard were worth $951,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the stock. Dimensional Fund Advisors LP increased its position in C.R. Bard by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 235,925 shares of the medical instruments supplier’s stock worth $53,003,000 after buying an additional 2,748 shares during the period. Allianz Asset Management AG increased its position in C.R. Bard by 85.1% in the fourth quarter. Allianz Asset Management AG now owns 55,853 shares of the medical instruments supplier’s stock worth $12,548,000 after buying an additional 25,674 shares during the period. Cantab Capital Partners LLP purchased a new position in C.R. Bard during the fourth quarter worth approximately $200,000. Cigna Investments Inc. New purchased a new position in C.R. Bard during the fourth quarter worth approximately $625,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of C.R. Bard during the fourth quarter worth about $231,000. Institutional investors own 87.63% of the company’s stock.
Shares of C.R. Bard, Inc. (NYSE BCR) traded up 0.10% during mid-day trading on Friday, reaching $322.22. 407,777 shares of the company’s stock traded hands. The stock has a market cap of $23.33 billion, a PE ratio of 41.01 and a beta of 0.59. The firm has a 50 day moving average price of $316.17 and a 200-day moving average price of $273.92. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $322.85.
C.R. Bard (NYSE:BCR) last released its earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, beating the consensus estimate of $2.65 by $0.22. C.R. Bard had a net margin of 15.70% and a return on equity of 48.72%. The firm had revenue of $938.80 million for the quarter, compared to analyst estimates of $916.15 million. During the same period last year, the firm earned $2.34 EPS. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, analysts predict that C.R. Bard, Inc. will post $11.78 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, August 4th. Shareholders of record on Monday, July 24th will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend is Thursday, July 20th. C.R. Bard’s dividend payout ratio is currently 13.21%.
COPYRIGHT VIOLATION WARNING: This article was first published by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.baseball-news-blog.com/2017/07/22/liberty-mutual-group-asset-management-inc-sells-1184-shares-of-c-r-bard-inc-bcr-updated-updated.html.
A number of equities analysts have issued reports on BCR shares. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 target price on the stock in a report on Thursday, May 11th. Jefferies Group LLC reissued a “hold” rating and issued a $237.00 target price on shares of C.R. Bard in a report on Monday, March 27th. Morgan Stanley cut C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. BMO Capital Markets restated a “buy” rating and issued a $255.00 price target on shares of C.R. Bard in a research report on Tuesday, April 11th. Finally, Raymond James Financial, Inc. lowered shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research report on Wednesday, April 26th. Eleven analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $271.31.
In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the firm’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the transaction, the vice president now directly owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.80% of the stock is owned by company insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for C.R. Bard Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.